Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation

Oncogene

Volumn 34, Issue 6, 2015, Pages 691-703

  Yin, M ^a,b   Ren, X ^a,b   Zhang, X ^c   Luo, Y ^d   Wang, G ^a   Huang, K ^d,e   Feng, S ^d   Bao, X ^a   He, X ^b   Liang, P ^a,e   Wang, Z ^a   Tang, H ^c   He, J ^c   Zhang, B ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d Guangzhou Science Park   (China)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

lung cancer; miR 506; NF B p65; p53; ROS; selective killing

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MIRN506 MICRORNA, HUMAN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; CARCINOGENESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICRORNAS; NF-KAPPA B; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85028193005     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.597     Document Type: Article

References (58)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252-263.
3. Linzer DI, Levine AJ. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52.
4. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
5. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-1307.
6. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-1134.
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
8. Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008; 98: 4-8.
9. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979-987.
10. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
11. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature 2006; 441: 431-436.
12. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25: 6817-6830.
13. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kB activation: From bench to bedside. Exp Biol Med 2008; 233: 21-31.
14. Perkins ND. Integrating cell-signalling pathways with NF-kappa B and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
15. Li F, Sethi G. Targeting transcription factor NF-kappa B to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010; 1805: 167-180.
16. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011; 61: 91-112.
17. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009; 8: 579-591.
18. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995; 358: 1-3.
19. Visconti R, Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Dev 2009; 12: 240-245.
20. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011; 71: 1385-1396.
21. Cheng YH, Liu XJ, Zhang SO, Lin Y, Yang J, Zhang CX. MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47: 5-14.
22. Ebi H, Sato T, Sugito N, Hosono Y, Yatabe Y, Matsuyama Y et al. Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009; 28: 3371-3379.
23. Zhang R, Peng Y, Wang W, Su B. Rapid evolution of an X-linked microRNA cluster in primates. Genome Res 2007; 17: 612-617.
24. Perkins ND. The diverse and complex roles of NF-kappa B subunits in cancer. Nat Rev Cancer 2012; 12: 121-132.
25. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappa B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
26. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, Olinski R. Oxidative DNA-base damage and antioxidant enzyme-activities in human lung-cancer. FEBS Lett 1994; 341: 59-64.
27. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 2000; 32: 157-170.
28. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein-induced in human-skin fibroblasts by UVA radiation, hydrogen-peroxide and sodium arsenite. Proc Natl Acad Sci USA 1989; 86: 99-103.
29. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006; 13: 941-950.
30. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460: 529-U111.
31. Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitorinduced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005; 25: 5429-5444.
32. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-107.
33. Basseres DS, Ebbs A, Levantini E, Baldwin AS. Requirement of the NF-kappa B subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 2010; 70: 3537-3546.
34. Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012; 31: 1558-1570.
35. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472-15477.
36. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011; 17: 1627-U1144.
37. Yang D, Sun Y, Hu LM, Zheng H, Ji P, Pecot CV et al. Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013; 23: 705-705.
38. Arora H, Qureshi R, Park WY. miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One 2013; 8: e64273.
39. Tang XM, Liu DN, Shishodia S, Ozburn N, Behrens C, Lee JJ et al. Nuclear factorkappa B (NF-kappa B) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006; 107: 2637-2646.
40. Hsu YL, Kuo PL, Lin CC. Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci 2004; 75: 2303-2316.
41. Weinstein IB. Cancer: addiction to oncogenes-The Achilles heal of cancer. Science 2002; 297: 63-64.
42. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappa B addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011; 30: 1615-1630.
43. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
44. Dijsselbloem N, Goriely S, Albarani V, Gerlo S, Francoz S, Marine JC et al. A critical role for p53 in the control of NF-kappa B-dependent gene expression in TLR4-stimulated dendritic cells exposed to genistein. J Immunol 2007; 178: 5048-5057.
45. Liu G, Park YJ, Tsuruta Y, Lorne E, Abraham E. p53 attenuates lipopolysaccharideinduced NF-kappa B activation and acute lung injury. J Immunol 2009; 182: 5063-5071.
46. Gurova KV, Hill JE, Guo CH, Prokvolit A, Burdelya LG, Samoylova E et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappa B-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102: 17448-17453.
47. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. Nutlin-3 inhibits the NF kappa B pathway in a p53-dependent manner implications in lung cancer therapy. Cell Cycle 2007; 6: 2178-2185.
48. Amin AR, Khuri FR, Chen ZG, Shin DM. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prevent Res 2009; 2: 538-545.
49. Adhikary A, Mohanty S, Lahiry L, Hossain DMS, Chakraborty S, Das T. Theaflavins retard human breast cancer cell migration by inhibiting NF-kappa B via p53-ROS cross-talk. FEBS Lett 2010; 584: 7-14.
50. Priyadarsini RV, Murugan RS, Maitreyi S, Ramalingam K, Karunagaran D, Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kappa B inhibition. Eur J Pharmacol 2010; 649: 84-91.
51. Hileman EO, Liu JS, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004; 53: 209-219.
52. Pelicano H, Carney D, Huang P. ROSstress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7: 97-110.
53. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10: 241-252.
54. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li XY et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475: 231-234.
55. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T et al. p53-responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
56. Yamakuchi M, Lotterman CD, Bao C, Hruban R, Karim B, Mendell JT et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107: 6334-6339.
57. Banales JM, Saez E, Uriz M, Splinter P, Bogert PST, Prieto J et al. Upregulation of Mir-506 leads to decreased Ae2 expression in biliary epithelium of patients with primary biliary cirrhosis. J Hepatol 2012; 56: S15-S15.
58. Feng SP, Cong SJ, Zhang X, Bao XC, Wang W, Li HP et al. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res 2011; 39: 6669-6678.